TRENDS IN INCIDENCE AND MORTALITY OF OVARIAN CANCER IN THE REPUBLIC OF TAJIKISTAN: ANALYSIS BASED ON THE CLINICAL MATERIAL OF PATIENTS WITH PERITONEAL CARCINOMATOSIS WHO RECEIVED PIPAC
Abstract
This article examines contemporary issues related to the epidemiology, pathogenesis, diagnosis, and treatment strategy of ovarian cancer. Based on an analysis of high-level international sources (CA Cancer J Clin, The Lancet, NCCN, ESMO) and modern clinical experience, the main trends in disease incidence and mortality, as well as the specific features of peritoneal carcinomatosis spread, are considered.
References
1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: A Cancer Journal for Clinicians. – 2021. – Vol. 71, № 3. – P. 209-249. – DOI: 10.3322/caac.21660.
2. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA: A Cancer Journal for Clinicians. – 2024. – DOI: 10.3322/caac.21834.
3. International Agency for Research on Cancer. Tajikistan fact sheet. GLOBOCAN 2022 (version 1.1, 08.02.2024). – Lyon: IARC, 2024.
4. Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D., Gaudet M.M., Jemal A., Siegel R.L. Ovarian cancer statistics, 2018 // CA: A Cancer Journal for Clinicians. – 2018. – Vol. 68, № 4. – P. 284–296. – DOI: 10.3322/caac.21456.
5. Lheureux S., Gourley C., Vergote I., Oza A.M. Epithelial ovarian cancer // The Lancet. – 2019. – Vol. 393, № 10177. – P. 1240–1253. – DOI: 10.1016/S0140-6736(18)32552-2.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma // Nature. – 2011. – Vol. 474, № 7353. – P. 609–615. – DOI: 10.1038/nature10166.
7. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., et al. Driver mutations in TP53 are ubiquitous in high-grade serous carcinoma of the ovary // The Journal of Pathology. – 2010. – Vol. 221, № 1. – P. 49–56. – DOI: 10.1002/path.2696.
8. Lheureux S., Braunstein M., Oza A.M. Epithelial ovarian cancer: evolution of management in the era of precision medicine // CA: A Cancer Journal for Clinicians. – 2019. – Vol. 69, № 4. – P. 280–304. – DOI: 10.3322/caac.21559.
9. Al Rawahi T., Lopes A.D., Bristow R.E. Surgical cytoreduction in advanced ovarian cancer // Gynecologic Oncology. – 2013. – Vol. 129. – P. 377–382. – DOI: 10.1016/j.ygyno.2013.02.051.
10. González-Martín A., Harter P., Leary A., Lorusso D., Moore K.N., Oaknin A., et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // Annals of Oncology. – 2023. – Vol. 34, № 10. – P. 833–848. – DOI: 10.1016/j.annonc.2023.07.011.
11. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer // The New England Journal of Medicine. – 2006. – Vol. 354, № 1. – P. 34–43. – DOI: 10.1056/NEJMoa052985.
12. van Driel W.J., Koole S.N., Sikorska K., Schagen van Leeuwen J.H., Schreuder H.W.R., Hermans R.H.M., et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer // The New England Journal of Medicine. – 2018. – Vol. 378, № 3. – P. 230–240. – DOI: 10.1056/NEJMoa1708618.
13. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA trial // Journal of Clinical Oncology. – 2014. – Vol. 32, № 13. – P. 1302–1308. – DOI: 10.1200/JCO.2013.51.4489.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. Version 3.2026. – Plymouth Meeting, PA: NCCN, 2026.
15. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESGO–ESMO–ESP consensus recommendations // Annals of Oncology. – 2024.
16. Böhm S., Faruqi A., Said I., Lockley M., Brockbank E., Jeyarajah A., et al. Chemotherapy Response Score (CRS) // Journal of Clinical Oncology. – 2015. – Vol. 33. – DOI: 10.1200/JCO.2014.60.5212.
17. Solass W., Sempoux C., Detlefsen S., Carr N.J., Bibeau F. Peritoneal Regression Grading Score (PRGS) // Pleura and Peritoneum. – 2016. – Vol. 1, № 2. – P. 99–107. – DOI: 10.1515/pp-2016-0011.
18. Baake J., Horvath P., Struller F., Königsrainer A., Reibetanz J., Piso P., et al. PRGS prognostic significance // Pleura and Peritoneum. – 2023. – DOI: 10.1515/pp-2023-0007.
19. Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer epidemiology // International Journal of Women’s Health. – 2019. – Vol. 11. – P. 287–299. – DOI: 10.2147/IJWH.S197604.
20. Taliento C., Restaino S., Scutiero G., Arcieri M., Bernardi G., Martinello R., et al. PIPAC systematic review // European Journal of Surgical Oncology. – 2023. – Vol. 49, № 12. – Art. 107250. – DOI: 10.1016/j.ejso.2023.107250.
21. Pavone M., Perrone A.M., Scarpelli E., Salutari V., Scutiero G., De Iaco P., et al. PIPAC safety and efficacy // Archives of Gynecology and Obstetrics. – 2024. – Vol. 310, № 4. – P. 1845–1856. – DOI: 10.1007/s00404-024-07586-z.
22. Vizzielli G., Giudice M.T., Nardelli F., Costantini B., Salutari V., Inzani F.S., et al. PARROT Trial // Annals of Surgical Oncology. – 2024. – Vol. 31, № 2. – P. 1207–1216. – DOI: 10.1245/s10434-023-14648-0.
23. Tesei M., Scarpelli E., Giudice M.T., Costantini B., Fiuzzi E., Coada C.A., et al. PIPAC multi-institutional study // European Journal of Surgical Oncology. – 2026. – Vol. 52, № 1. – Art. 111161. – DOI: 10.1016/j.ejso.2025.111161.
24. Moore K., Colombo N., Scambia G., Kim B.-G., Oaknin A., Friedlander M., et al. Maintenance olaparib // The New England Journal of Medicine. – 2018. – Vol. 379, № 26. – P. 2495–2505.
25. DiSilvestro P., Banerjee S., Colombo N., Scambia G., Kim B.-G., Oaknin A., et al. SOLO1 trial // Journal of Clinical Oncology. – 2023. – Vol. 41, № 3. – P. 609–617.
26. González-Martín A., Pothuri B., Vergote I., et al. Niraparib trial // The New England Journal of Medicine. – 2019.
27. Ray-Coquard I., Pautier P., Pignata S., et al. Olaparib + bevacizumab // The New England Journal of Medicine. – 2019.
28. Ali A.T. Epidemiology and risk factors for ovarian cancer // Seminars in Cancer Biology. – 2023.
29. Lee J.Y., Kim H.S., Chung H.H., et al. CRS validation // Journal of Gynecologic Oncology. – 2017.
30. Said I., Böhm S., Beasley J., et al. CRS reproducibility // International Journal of Gynecological Pathology. – 2017.
